B

BioDelivery Sciences International Inc
F:BD5

Watchlist Manager
BioDelivery Sciences International Inc
F:BD5
Watchlist
Price: 5.05 EUR Market Closed
Market Cap: €521.3m

Gross Margin

101.1%
Current
No historical data
Comparison unavailable

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
101.1%
=
Gross Profit
$143.3m
/
Revenue
$166.7m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
101.1%
=
Gross Profit
€143.3m
/
Revenue
$166.7m

Peer Comparison

Country Company Market Cap Gross
Margin
US
BioDelivery Sciences International Inc
F:BD5
499.2m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 99% of companies in the United States of America
Percentile
99th
Based on 12 729 companies
99th percentile
101.1%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

BioDelivery Sciences International Inc
Glance View

Market Cap
521.3m EUR
Industry
Pharmaceuticals

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.

BD5 Intrinsic Value
Not Available
B
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
101.1%
=
Gross Profit
$143.3m
/
Revenue
$166.7m
How has Gross Margin changed over time?

Over the last 3 years, BioDelivery Sciences International Inc’s Gross Margin has increased from 82.2% to 101.1%. During this period, it reached a low of 82.2% on Dec 1, 2018 and a high of 102.9% on Dec 31, 2020.

Back to Top